🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Indoco Remedies Limited INDOCO NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.indoco.com
Company Profile ↓
₹253.98
-22.25% 1Y
Mkt Cap₹2,344.33 Cr
P/E-30.02
P/B2.32
Div. Yield0.08%
52W High₹338.86
52W Low₹164.00
Book Value₹101.76
EPS (TTM)₹-8.46

Company Overview

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,792.94 Cr (+9.2% YoY); net profit ₹-95.15 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +9.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.0%, profit CAGR -55.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.02%
1 Year:9.24%

Compounded Profit Growth

5 Years:-55.63%
1 Year:-

Stock Price Performance

1 Year:-22.25%
6 Months:+16.64%
3 Months:+17.00%
1 Month:+6.01%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 51% of range
₹164.00 ₹338.86
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.82 · Neutral
Price Performance
1M+6.01%
3M+17.00%
6M+16.64%
1Y-22.25%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -55.6% CAGR over 5 years.
  • Trading 25.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-30.02
Industry PE
39.97
Forward P/E
18.68
PEG Ratio
-
Book Value
₹101.76
Price to Book
2.32
P/S
1.29
EV/EBITDA
22.78
Dividend Yield
0.08%

Growth (CAGR)

Revenue 5Y
3.02%
Profit 5Y
-55.63%
Revenue (YoY)
9.24%
Earnings (YoY)
-

Profitability & Returns

ROCE
1.02%
ROE
-10.13%
ROA
-3.67%
Profit Margin
-5.31%
Op Margin
0.86%
Gross Margin
69.78%
EPS (Latest Qtr)
₹-2.57
EPS (TTM)
₹-8.46

Balance Sheet & Liquidity

Debt/Equity
1.16
Quick Ratio
0.75
Current Ratio
1.13
Debt
₹1,089.75 Cr
Total Assets
₹2,593.27 Cr
Current Assets
₹1,193.35 Cr
Working Capital
₹140.81 Cr

Ownership

Promoter Holding
60.89%
Chg in Prom Hold
2.03%
FII / Inst Holding
19.70%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹2,344.33 Cr
Total Revenue (TTM)
₹1,792.94 Cr
EBITDA
₹142.19 Cr
Free Cash Flow
₹101.00 Cr
Operating Cash Flow
₹226.35 Cr
Shares Outstanding
₹9.23 Cr
Gross Margin
69.78%
Payout Ratio
45.39%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INDOCO Indoco Remedies Limited NSEPHARMA 253.98 -30.02 ₹2,344.33 Cr 0.08% 1.02% -10.13% 3.02% -55.63%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 428.00 Cr426.00 Cr482.00 Cr459.00 Cr450.00 Cr431.00 Cr433.00 Cr411.00 Cr383.89 Cr429.08 Cr471.83 Cr434.34 Cr455.90 Cr
Cost of Revenue --------105.97 Cr134.97 Cr145.34 Cr120.42 Cr141.01 Cr
Gross Profit --------277.92 Cr294.11 Cr326.49 Cr313.92 Cr314.89 Cr
Operating Expenses 363.00 Cr365.00 Cr410.00 Cr397.00 Cr401.00 Cr384.00 Cr392.00 Cr399.00 Cr307.48 Cr306.28 Cr315.69 Cr314.42 Cr297.67 Cr
Operating Income 47.00 Cr41.00 Cr50.00 Cr39.00 Cr23.00 Cr20.00 Cr11.00 Cr-17.00 Cr-29.56 Cr-12.17 Cr10.80 Cr-50.00 L17.22 Cr
EBITDA 65.00 Cr61.00 Cr71.00 Cr63.00 Cr49.00 Cr48.00 Cr40.00 Cr12.00 Cr1.24 Cr19.16 Cr43.28 Cr26.34 Cr53.41 Cr
Interest Expense 9.00 Cr8.00 Cr8.00 Cr10.00 Cr12.00 Cr14.00 Cr18.00 Cr16.00 Cr17.98 Cr26.12 Cr24.56 Cr25.64 Cr45.92 Cr
Pretax Income 39.00 Cr34.00 Cr46.00 Cr23.00 Cr33.00 Cr7.00 Cr-5.00 Cr-31.00 Cr-45.52 Cr-36.66 Cr-13.53 Cr-31.31 Cr-25.00 Cr
Tax Provision 13.26 Cr9.86 Cr11.04 Cr7.13 Cr10.89 Cr5.18 Cr-5.35 Cr2.48 Cr-4.18 Cr-31.00 L-4.32 Cr-1.86 Cr-1.32 Cr
Net Income 26.00 Cr24.00 Cr35.00 Cr16.00 Cr22.00 Cr2.00 Cr-10.00 Cr-28.00 Cr-40.39 Cr-35.79 Cr-7.93 Cr-29.79 Cr-21.64 Cr
Diluted EPS 2.802.653.811.772.460.28-1.04-2.86-4.48-3.94-1.00-3.20-2.57

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 854.00 Cr1,005.00 Cr1,071.00 Cr1,041.00 Cr968.00 Cr1,107.00 Cr1,242.00 Cr-1,640.05 Cr1,788.22 Cr1,641.29 Cr1,792.94 Cr
Cost of Revenue --------539.31 Cr582.10 Cr498.18 Cr541.74 Cr
Gross Profit --------1,100.73 Cr1,206.12 Cr1,143.11 Cr1,251.20 Cr
Operating Expenses 689.00 Cr834.00 Cr914.00 Cr906.00 Cr892.00 Cr983.00 Cr1,017.00 Cr-903.10 Cr1,063.26 Cr1,157.69 Cr1,235.85 Cr
Operating Income 119.00 Cr110.00 Cr94.00 Cr67.00 Cr5.00 Cr52.00 Cr152.00 Cr-197.64 Cr142.86 Cr-14.58 Cr15.35 Cr
EBITDA 166.00 Cr171.00 Cr157.00 Cr135.00 Cr77.00 Cr123.00 Cr225.00 Cr-287.15 Cr262.59 Cr105.70 Cr142.19 Cr
Interest Expense 11.00 Cr12.00 Cr6.00 Cr24.00 Cr21.00 Cr26.00 Cr22.00 Cr-23.75 Cr34.93 Cr66.23 Cr122.25 Cr
Pretax Income 110.00 Cr99.00 Cr91.00 Cr48.00 Cr-9.00 Cr29.00 Cr132.00 Cr-192.79 Cr135.80 Cr-74.37 Cr-106.51 Cr
Tax Provision 26.40 Cr16.83 Cr13.65 Cr7.20 Cr6.21 Cr4.64 Cr39.60 Cr-50.54 Cr38.79 Cr3.58 Cr-7.81 Cr
Net Income 83.00 Cr82.00 Cr77.00 Cr41.00 Cr-3.00 Cr24.00 Cr93.00 Cr-142.25 Cr98.46 Cr-73.74 Cr-95.15 Cr
Diluted EPS 8.998.898.364.47-0.312.6210.1016.8015.4210.67-8.46-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 846.00 Cr941.00 Cr1,197.00 Cr1,238.00 Cr1,258.00 Cr1,272.00 Cr1,315.00 Cr-1,658.20 Cr2,144.73 Cr2,429.91 Cr2,593.27 Cr
Current Assets --------813.57 Cr954.67 Cr1,001.34 Cr1,193.35 Cr
Cash & Equivalents --------10.92 Cr14.86 Cr12.10 Cr25.93 Cr
Inventory --------325.99 Cr353.06 Cr419.35 Cr405.21 Cr
Receivables --------350.94 Cr406.20 Cr352.41 Cr489.17 Cr
Total Liabilities --------629.95 Cr1,034.23 Cr1,411.54 Cr1,661.16 Cr
Current Liabilities --------424.51 Cr612.33 Cr807.99 Cr1,052.54 Cr
Long Term Debt --------143.50 Cr351.73 Cr533.20 Cr516.02 Cr
Total Debt 97.00 Cr140.00 Cr280.00 Cr282.00 Cr296.00 Cr262.00 Cr267.00 Cr-332.85 Cr671.95 Cr993.57 Cr1,089.75 Cr
Total Equity 518.00 Cr576.00 Cr651.00 Cr675.00 Cr660.00 Cr679.00 Cr769.00 Cr-1,028.25 Cr1,109.90 Cr1,022.00 Cr939.28 Cr
Shares Outstanding --------9.22 Cr9.22 Cr9.22 Cr9.23 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 109.00 Cr112.00 Cr89.00 Cr123.00 Cr132.00 Cr123.00 Cr82.00 Cr-178.83 Cr155.39 Cr90.76 Cr226.35 Cr
Investing Cash Flow -88.00 Cr-111.00 Cr-171.00 Cr-135.00 Cr-104.00 Cr-56.00 Cr-67.00 Cr--208.17 Cr-432.52 Cr-259.79 Cr-87.38 Cr
Financing Cash Flow -20.00 Cr-2.00 Cr132.00 Cr-39.00 Cr-16.00 Cr-64.00 Cr-30.00 Cr-22.80 Cr280.43 Cr168.62 Cr-133.09 Cr
Capital Expenditure -89.00 Cr-97.00 Cr-189.00 Cr-138.00 Cr-93.00 Cr-59.00 Cr-76.00 Cr--207.25 Cr-425.99 Cr-258.43 Cr-125.35 Cr
Free Cash Flow 20.00 Cr15.00 Cr-100.00 Cr-15.00 Cr39.00 Cr64.00 Cr6.00 Cr--28.42 Cr-270.60 Cr-167.67 Cr101.00 Cr
Net Change in Cash 1.00 Cr-050.00 Cr-51.00 Cr12.00 Cr3.00 Cr-14.00 Cr--6.54 Cr3.31 Cr-41.00 L5.88 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------67.1%67.4%69.6%69.8%
Operating Margin % 13.9%10.9%8.8%6.4%0.5%4.7%12.2%-12.1%8.0%-0.9%0.9%
Net Margin % 9.7%8.2%7.2%3.9%-0.3%2.2%7.5%-8.7%5.5%-4.5%-5.3%
ROE % 16.0%14.2%11.8%6.1%-0.5%3.5%12.1%-13.8%8.9%-7.2%-10.1%
ROCE % --------16.0%9.3%-0.9%1.0%

Shareholding Pattern

Insiders
60.89%
Institutions
19.70%
Public Float
50.36%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INDOCO

Google News Wed, 11 Feb 2026

Indoco Remedies (NSE:INDOCO investor three-year losses grow to 42% as the stock sheds ₹2.2b this past week - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOVXRyRHlSVzRQSDVTV2Z5eGZwTHJXb1VqaldrZ3NHWVU2aV9ncUZrN2NvdUNiSnRYVzluUFJ3SlV3TkJPUU9BQ0lKUUVrTzNVUVNsdFItZkVGZFR0NXhoTHo3azR5aGwwdjZsOXdXZENYVWJycG5GQmpvS1cxWnZiSGNORmpPUGM4Ql9OTV…

Google News Mon, 29 Jun 2026

Indoco Remedies share price gains after Goa plant receives EU GMP certification - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPcEFBZWpiWHZNcmRELXFBcDVteHRsQWdvMlNaSkppaTRmdlpfaWRWdkdabzJXQ3p5YVNfS1psbDNtMGFXYk1xTS1qTTlDZ3N4WGRwUnp1NmdsVVYzZnJpcllpM0tGTkRMMS1ySC10NUZMR2lqTHI2VFZBV3FEc203NDNYX2s3UEMwT3ZKSl…

Google News hu, 07 May 2026

Indoco Remedies Q4 Results: Loss halves, EBITDA returns to profit; shares rally 13% - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPNmRNU2VxZnB3OWhNNU1ad3YzdEE1WVhMTG00OFJEUU0zOVI5aTRnNXpyTmJsTkNOX09sQ2x6QmJpeUtNSU9ZV0hOX0NCc2tPZDVxalVRWWIzbVBpU2pUY2wxbVU5N3ZMdUdIakxxX3JmVFN0NWpBXzN4LU0tSEZNM2xrWXdCalU2bzV3SV…

Google News hu, 11 Jun 2026

Indoco Remedies Share Price Today Up 14% - Equitymaster

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPZllyVEpRQ1QtSHVENEJnOVhfS1A5RElxOHZEdU9kclNnbEJiX0pTeWlsVWxlNE95dUMyai1nQjNsR29mSUYxalRFLXpicnh2aXUtYkZGTmVkem5Ob1NhUW9YdDNnNUFuYnZ3cVBFVWtucTBQZmc4d2JHN3YwTklXekJaYzFkV0txTWxTZk…

Google News Fri, 30 Jan 2026

Indoco Remedies Shares Soar 7% on Securing USFDA Final Approval - Equitypandit

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPdHRrQnJ6X2JzRmlHQUg0Z3hMc1ViVWp3R2ZOcEprNWlZNGxQcWFLV0ozZHYtalBOSXpzQW5nM1VQai1odDNDOHJDc1lDM3Ewc2lXcy1NanRfV3pyY2pKbmlJYnFzWmU1a3JYWjRGZEViOFJFUEVJWDJOVjZUOGY2aXV3U2xJMFpTaFdtdm…

Google News Fri, 12 Dec 2025

Indoco Remedies shares rise 5% on receiving EIR for Patalganga API unit - Business Standard

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOQWhzR3dzTDAweml0aUMtSGdPUEJwZHBlT0JJTXREOC1lQTlJT1FrWE5TR3ZJSzV4UDlRMElBLUVKOV9MX2xTMUU3VlF2Wk14TTFtbHkyeWJmR3FOeGFjdnhJRVZVanQ3RVIxY19oUHkyeFpjQjV2dm1YUFVJUWMxLXNSYzlEbG5kZ1J4Qn…

INDOCO — Frequently Asked Questions

What is the current share price of Indoco Remedies Limited (INDOCO)?

As of 2026-07-15 09:52 IST, Indoco Remedies Limited (INDOCO) trades at ₹253.98 on NSE. Its 52-week range is ₹164.00 to ₹338.86.

What is the market capitalisation of INDOCO?

Indoco Remedies Limited (INDOCO) has a market capitalisation of ₹2,344.33 Cr on NSE.

What is the P/E ratio of INDOCO?

INDOCO trades at a trailing price-to-earnings (P/E) ratio of -30.02. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.32.

Does INDOCO pay a dividend?

Indoco Remedies Limited (INDOCO) currently offers a dividend yield of 0.08%.

What is the return on equity (ROE) of INDOCO?

INDOCO has a return on equity (ROE) of -10.13%. Its return on capital employed (ROCE) is 1.02%.

Is INDOCO a good stock to buy?

This page provides a data-driven analysis of Indoco Remedies Limited (INDOCO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space